Clinical trial
Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's…
NCT00185731 · Dean Felsher, Other · Completed
Key facts
| NCT number | NCT00185731 |
|---|---|
| Title | Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Atorvastatin in Patients With Low Grade or Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | Dean Felsher, Other |
| Collaborators | The Leukemia and Lymphoma Society Damon Runyon Cancer Research Foundation Burroughs Wellcome Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Atorvastatin |
| Enrollment | 25 |
| Start date | Apr 1, 2005 |
| Primary completion | Nov 1, 2012 |
| Completion | Nov 1, 2012 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: